CytoMed Therapeutics (GDTC) Long-Term Investments (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Long-Term Investments of $14050.4 for Q4 2025, down 93.32% sequentially from $210349.0 in Q2 2025, and down 91.54% YoY from $166105.0 in Q4 2024.
CytoMed Therapeutics (GDTC) Long-Term Investments (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Long-Term Investments for 5 years, with the latest figure at $14050.4 in Q4 2025.
- Quarterly Long-Term Investments fell 91.54% year-over-year to $14050.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14050.4 (down 91.54% YoY) and the FY2025 annual result came in at $13937.9, down 91.57% from the prior year.
- Long-Term Investments declined to $14050.4 in Q4 2025 per GDTC's latest filing, from $210349.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $219667.0 in Q2 2023 and troughed at $14050.4 in Q4 2025.
- A 5-year average of $167417.7 and a median of $186834.2 in 2021 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments advanced 14.96% in 2024, then slumped 91.54% in 2025.
- Over 5 years, Long-Term Investments stood at $201148.6 in 2021, then fell by 14.23% to $172519.8 in 2022, then retreated by 16.25% to $144489.1 in 2023, then gained by 14.96% to $166105.0 in 2024, then sank by 91.54% to $14050.4 in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $14050.4, $210349.0, and $166105.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,050.43 |
| Jun 30, 2025 | 210,349.00 |
| Dec 31, 2024 | 166,105.01 |
| Jun 30, 2024 | 211,013.00 |
| Dec 31, 2023 | 144,489.10 |
| Jun 30, 2023 | 219,667.00 |
| Dec 31, 2022 | 172,519.83 |
| Dec 31, 2021 | 201,148.59 |